Stoke Therapeutics (NASDAQ:STOK) Director Sells 12,567 Shares of Stock

by · The Markets Daily

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) Director Edward Md Kaye sold 12,567 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stoke Therapeutics Stock Performance

Shares of STOK traded up $0.01 during midday trading on Tuesday, hitting $32.14. 574,554 shares of the stock traded hands, compared to its average volume of 816,472. Stoke Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $40.22. The business’s 50 day moving average price is $30.81 and its two-hundred day moving average price is $32.21. The firm has a market capitalization of $2.07 billion, a PE ratio of -9.62 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Stoke Therapeutics during the 2nd quarter worth about $192,307,000. Jupiter Topco LLC acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter worth approximately $59,358,000. Janus Henderson Group PLC grew its holdings in shares of Stoke Therapeutics by 333.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after purchasing an additional 1,116,452 shares in the last quarter. State Street Corp raised its stake in shares of Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after purchasing an additional 1,072,176 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Stoke Therapeutics in the second quarter worth $7,489,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on STOK. Wedbush raised their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Finally, Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.00.

View Our Latest Stock Analysis on STOK

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

See Also